Full-Time

Commercial Diagnostics Manager

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

Orlando, FL, USA + 8 more

More locations: Knoxville, TN, USA | Tampa, FL, USA | Miami, FL, USA | Raleigh, NC, USA | Richmond, VA, USA | Columbia, SC, USA | Atlanta, GA, USA | Roanoke, VA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Marketing
Requirements
  • Bachelor’s degree in Life Sciences, Business Administration, or a related field.
  • Minimum of 7 years of experience in the pharmaceutical, biotech, or related industries.
  • At least 5 years of experience in sales management, market access, marketing, or clinical roles in a similar therapeutic area.
  • Proven success in engaging IDNs/health systems or ACOs.
  • Demonstrated ability to influence without authority and lead cross-functional teams effectively.
  • Exceptional communication, organizational, and analytical skills.
Responsibilities
  • Develop and execute account-specific compliant diagnostic strategies for IDNs/health systems, ACOs and influential physician groups in appropriate matrix collaboration with Sales, Marketing, Medical Affairs, and Market Access teams.
  • Partner with IDN/CAD teams to increase diagnosis Identify and implement pathways to accelerate screening and diagnosis of hATTR-PN.
  • Lead high-level discussions with C-suite executives and key decision-makers to educate stakeholders on diagnostic protocols, early patient identification, and high-quality care pathways for hATTR-PN.
  • Build and sustain strategic relationships with key customers including non-treating diagnostic MD’s, genetic counsellors, non-treating multidisciplinary team involved in testing process (nurse, patient navigators), and advocacy groups.
  • Collaborate with internal and external stakeholders to identify and address system-level barriers to testing and improve patient identification initiatives.
  • Enhance diagnostic expertise to accelerate timely and accurate patient diagnosis, reducing misdiagnosis and minimizing disease impact.
  • Communicate cross functionally, in real time, to ensure cohesive alignment and execution across key accounts.
  • Drive collaboration with diagnostic and laboratory stakeholders to enhance biomarker testing workflows and access.
  • Ensure all activities and engagements are approved and adhere to AstraZeneca’s Code of Ethics and regulatory compliance guidelines.
Desired Qualifications
  • Experience in multiple commercial functions, such as District Sales Manager, Brand/ Marketing and/or similar leadership experience.
  • Expertise in rare diseases, biologics, and/or specialty products.
  • Familiarity with cardiology, neurology, and/or biomarker diagnostics.

AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA approval of Imfinzi boosts AstraZeneca's oncology portfolio.
  • Calquence's EU recommendation strengthens AstraZeneca's position in hematology treatments.
  • AstraZeneca's $11B investment in China enhances its global R&D capabilities.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Biosimilars could reduce sales of AstraZeneca's biologic drugs.
  • Geopolitical tensions may disrupt AstraZeneca's supply chain and market access.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D to create new and improved therapies.
  • AstraZeneca's Open Innovation program accelerates drug discovery through shared resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Mar 31st, 2025
Calquence Recommended For Eu Approval In 1L Mcl

Calquence recommended for EU approval in 1L MCL

PharmiWeb
Mar 31st, 2025
Calquence Plus Chemoimmunotherapy Recommended For Approval In The Eu By Chmp As First And Only Btk Inhibitor For 1St-Line Mantle Cell Lymphoma

Recommendation based on ECHO Phase III trial results which demonstrated over 16 months of progression-free survival improvement vs. chemoimmunotherapy alone. AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous hematopoietic stem cell transplantation. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the ECHO Phase III trial which were presented at the European Hematology Association 2024 Congress

Cision
Mar 31st, 2025
Imfinzi Approved In The Us For Bladder Cancer

Imfinzi approved in the US for bladder cancer

PharmiWeb
Mar 31st, 2025
Imfinzi Approved In The Us As First And Only Perioperative Immunotherapy For Patients With Muscle-Invasive Bladder Cancer

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone. AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and was based on results from the NIAGARA Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine

OncoDaily
Mar 26th, 2025
Sunil Verma: Four years ago, the cancer community lost one of its leaders, Jose Baselga

Sunil Verma, Global Head of Oncology, Medical at AstraZeneca's Oncology Business Unit, shared on LinkedIn: